Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06510491 · ClinicalTrials.gov registry record · Phase 2
Epcoritamab in Previously Treated WM
A Phase 2 study of Waldenstrom Macroglobulinemia and B-Cell Lymphoproliferative Disorder, sponsored by Gottfried von Keudell, MD PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT06510491: Recruiting Phase 2 study of Waldenstrom Macroglobulinemia and B-Cell Lymphoproliferative Disorder, sponsored by Gottfried von Keudell, MD PhD.
NCT06510491 is a Phase 2 study of Waldenstrom Macroglobulinemia and B-Cell Lymphoproliferative Disorder that is actively recruiting participants, run by Gottfried von Keudell, MD PhD. The registered enrollment target is 20 participants, below the 473-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06510491, a Phase 2 study of Waldenstrom Macroglobulinemia and B-Cell Lymphoproliferative Disorder, is actively recruiting participants, sponsored by Gottfried von Keudell, MD PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study is: -Epcoritamab (a type of antibody)
Primary Outcome
The overall response rate (ORR) was defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on modified IWWM6 criteria.
Conditions Studied
Interventions
- DRUG Epcoritamab
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT06510491 shows while recruiting
NCT06510491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 473-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 1 intervention - of which Epcoritamab is the first listed.
NCT06510491 reports a single indexed study location in Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06510491 about?
NCT06510491 is a clinical study titled "Epcoritamab in Previously Treated WM". This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study is: -Epcoritamab (a type of antibody)
What is the current status of trial NCT06510491?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-12-06. Estimated completion is 2027-12-31.
What conditions does trial NCT06510491 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder.
What interventions are being tested in trial NCT06510491?
The interventions under investigation include: Epcoritamab (DRUG).
Who is sponsoring clinical trial NCT06510491?
This trial is sponsored by Gottfried von Keudell, MD PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06510491 being conducted?
This trial has 3 study locations across Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06510491's enrollment target sits among peer trials
20 33rd of 34 higher than 2 of 34 other Waldenstrom Macroglobulinemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Waldenstrom Macroglobulinemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
RECRUITING · Phase 2
-
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
RECRUITING · Phase 2
-
Loncastuximab Tesirine in WM
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
-
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI